Home > Insider Trading > Filing (0001209191-10-018090)

Filing Details

Accession Number:: 0001209191-10-018090
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-19 13:00:00
Reporting Period:: 2010-03-18

Filing Date:: 2010-03-19
Accepted Time:: 2010-03-19 21:56:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1339455	Somaxon Pharmaceuticals Inc.	SOMX	Pharmaceutical Preparations (2834)	200161599

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1343266	W Richard Pascoe	Somaxon Pharmaceuticals, Inc. 3830 Valley Centre Drive, Suite 705-461 San Diego CA 92130	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2010-03-18	4,510	$6.50	15,490	No	4	S	Direct
Common Stock	Acquisiton	2010-03-18	100,000	$1.23	115,490	No	4	M	Direct
Common Stock	Disposition	2010-03-18	76,300	$5.62	39,190	No	4	S	Direct
Common Stock	Disposition	2010-03-18	15,100	$6.42	24,090	No	4	S	Direct
Common Stock	Disposition	2010-03-18	4,800	$7.53	19,290	No	4	S	Direct
Common Stock	Disposition	2010-03-18	2,600	$8.74	16,690	No	4	S	Direct
Common Stock	Disposition	2010-03-18	1,200	$9.58	15,490	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2010-03-18	100,000	$0.00	100,000	$1.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
143,333		2018-08-10	No	4	M	Direct

Footnotes

This sale of shares of common stock underlying vested restricted stock units was effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, with the proceeds remitted to the Company to cover the taxes withheld upon the vesting of 20,000 restricted stock untis March 18, 2010.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $6.343 to $6.5111 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer upon request, full information regarding the number of shares.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $5.035 to $6.03 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer upon request, full information regarding the number of shares.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $6.04 to $6.98 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer upon request, full information regarding the number of shares.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.05 to $7.98 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer upon request, full information regarding the number of shares.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $8.15 to $9.0471 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer upon request, full information regarding the number of shares.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $9.43 to $9.82 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer upon request, full information regarding the number of shares.
1/3 of the shares of Common Stock subject to this grant vested on the date of grant (June 9, 2009) and the remaining shares will vest and become exercisable in 24 equal monthly installments over the following two-year period.
Not applicable.